Intuit Inc (NASDAQ:INTU, XETRA:ITU) the financial technology company behind TurboTax, QuickBooks, Credit Karma, and Mailchimp, reported a strong start to fiscal 2026, surpassing Wall Street expectations across revenue and earnings.
Shares of Intuit moved higher afterhours on the update, adding 3% at about $657.
Analysts at Wedbush repeated their ‘Outperform’ rating and $225 price target on Palo Alto Networks Inc (NYSE:PANW, XETRA:5AP) after it reported fiscal first quarter results that modestly exceeded Wall Street expectations.
The company posted revenue of $2.47 billion, at the high end of its guidance range and slightly above the Street’s estimate of $2.46 billion.
Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) delivered another blockbuster quarter, with demand for its AI chips still running red-hot and its newest Blackwell products selling faster than the company can produce them.
Analysts at Bank of America and UBS said the results were so strong that Wall Street will likely need to raise its earnings forecasts for several years out.
Cracker Barrel Old Country Store (NASDAQ:CBRL) shareholders have shown strong support for CEO Julie Felss Masino after a controversial logo redesign earlier this year sparked public outcry and calls for leadership changes.
Preliminary results from the company’s annual meeting held on Thursday indicated that investors elected nine of 10 board nominees, including Masino.
Block Inc (NYSE:SQ) shares added almost 6% after the financial technology firm outlined its three-year outlook during its 2025 Investor Day and announced a $5 billion increase to its share repurchase program.
The company outlined plans for profitable growth and operating leverage through 2028, highlighting the scale of its ecosystems, including Cash App, Square, and Proto, alongside continued discipline in execution.
Abbott Laboratories (NYSE:ABT) on Thursday announced a definitive agreement to acquire cancer diagnostics company Exact Sciences (NASDAQ:EXAS) in a deal valued at approximately $21 billion.
Exact Sciences, known for its noninvasive colorectal cancer screening test Cologuard and multi-cancer early detection test Cancerguard, reported projected revenue of more than $3 billion this year, with high-teens organic growth.
Trust Stamp Inc (NASDAQ:IDAI, ISE:AIID) announced that it has been selected to participate in the 2026 Trust Village Incubator, a program that aims to connect startups, research institutions and industry leaders in digital trust and cybersecurity supported by EPFL Innovation Park, Trust Valley, SICPA, and Canton de Vaud.
The selection highlights Trust Stamp’s work in privacy-preserving identity technology, including its latest innovation, StableKey, which is built on the company’s patented Stable IT2 cryptosystem, according to the company.
Bath & Body Works Inc (NYSE:BBWI) tumbled on Thursday after the specialty retailer cut its full-year outlook and posted quarterly results that fell short of Wall Street estimates, citing soft consumer sentiment and weaker spending on discretionary items.
Shares of the company slid about 20% in premarket trading, hitting their lowest level in five years.
Bath & Body Works Inc (NYSE:BBWI) tumbled on Thursday after the specialty retailer cut its full-year outlook and posted quarterly results that fell short of Wall Street estimates, citing soft consumer sentiment and weaker spending on discretionary items.
Shares of the company slid about 20% in premarket trading, hitting their lowest level in five years.
Walmart Inc (NYSE:WMT, XETRA:WMT) shares traded nearly 4% higher premarket on Thursday after the retailer reported stronger-than-expected fiscal third quarter results and lifted its full-year outlook.
The company posted revenue of $179.5 billion, up 5.8% year-over-year and ahead of analyst expectations of roughly $177.5 billion.
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) shares climbed 9% to 4.01p after the company secured a European patent for POLB 001, its experimental treatment for severe influenza.
The London-listed group, which develops drugs that modulate the body’s immune response, said the European Patent Office had granted protection for the compound. POLB 001 blocks an enzyme called p38 MAP kinase, part of the body’s inflammation machinery, with the goal of preventing dangerous immune overreactions.